- Home
- BHRB vs PHAR Comparison
BHRB vs PHAR Comparison
Compare BHRB & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BHRB | PHAR |
|---|---|---|
| Founded | 1852 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 968.8M | 1.1B |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BHRB | PHAR |
|---|---|---|
| Price | $62.99 | $16.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $72.80 | $39.00 |
| AVG Volume (30 Days) | ★ 85.9K | 18.2K |
| Earning Date | 04-24-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.52% | N/A |
| EPS Growth | ★ 173.76 | N/A |
| EPS | ★ 7.72 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $36.62 | $10.04 |
| Revenue Next Year | $10.06 | $2.70 |
| P/E Ratio | ★ $8.09 | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $47.77 | $7.79 |
| 52 Week High | $70.90 | $21.34 |
Technical Indicators
Market Signals| Indicator | BHRB | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 50.39 | 54.21 |
| Support Level | $61.00 | $16.55 |
| Resistance Level | $66.00 | $17.60 |
| Average True Range (ATR) | 1.25 | 0.60 |
| MACD | 0.30 | 0.16 |
| Stochastic Oscillator | 80.03 | 77.43 |
Price Performance
Historical ComparisonAbout BHRB Burke & Herbert Financial Services Corp.
Burke & Herbert Financial Services Corp is the bank holding company. Through its subsidiary, it predominantly serves small to medium-sized businesses, their owners and employees, professional corporations, non-profits, and individuals with various banking products and financial services. Some of its products and service offerings include checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential mortgage, acquisition, construction, and development loans, online banking, mobile banking, and wealth and trust services. The company operates in a single segment, namely Community Banking.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.